Risk of All-Cause Mortality in Diabetic Patients Taking β ...

1 Risk of All-Cause Mortality in Diabetic Patients Taking -Blockers - mayo Clinic (17)30845-5/fulltext[2018/04/11 20:28:06]Home Login | Register | Claim Subscription | SubscribeShare this page DOI: |To read this article in full, please review your options for gaining access at the bottom of the of All-Cause Mortality in Diabetic Patients Taking -Blockers, , , PlumX MetricsMentionsNews Mentions: 2 Social MediaTweets: 18 CitationsCitation Indexes: 1see detailsArticle InfoAbstractFull TextImagesReferencesSupplemental MaterialsArticle ToolsPDF (495 KB)Download Images(.ppt)About Images & UsageEmail ArticleAdd to My Reading ListExport CitationCreate Citation AlertCited by in Scopus (1)Request PermissionsOrder Reprints(100 minimum order) Related Articles All Content Search Advanced SearchArticles & IssuesMultimediaCollectionsCMEA uthors & ReviewersReadersAdvertisersSubscribersMa yo Clinic< Previous ArticleNext Article >April 2018 Volume 93, Issue 4, Pages 409 418 Tetsuro Tsujimoto, MD, PhDHiroshi Kajio, MD, PhDMartin F.

2 Shapiro, MD, PhDTakehiroSugiyama, MD, MSHS, PhDAccess this article onScienceDirectWhat Ever Happened to CardioprotectionWith -Blockers?Risk of All-Cause Mortality in Diabetic Patients Taking -Blockers - mayo Clinic (17)30845-5/fulltext[2018/04/11 20:28:06]AbstractObjectiveTo assess the relationship between use of -blockers and All-Cause Mortality in Patients with and and MethodsUsing data from the US National Health and Nutrition Examination Survey 1999-2010, we conducted aprospective cohort study. The study participants were followed-up from the survey participation date untilDecember 31, 2011. We used a Cox proportional hazards model for All-Cause Mortality analysis. Themultivariate-adjusted hazard ratios (HRs) of the participants Taking -blockers were compared with those ofthe participants not Taking study included 2840 Diabetic participants and 14,684 nondiabetic participants.

3 Compared with diabeticparticipants not Taking a -blocker, All-Cause Mortality was significantly higher in Diabetic participants takingany -blocker (HR, ; 95% CI, ; P=.01), Taking a -selective -blocker (HR, ; 95% CI, ; P=.007), or Taking a specific -blocker (bisoprolol, metoprolol, and carvedilol) (HR, ; 95% CI, ; P=.01). In addition, All-Cause Mortality in Diabetic participants with coronary heart disease (CHD) wassignificantly higher in those Taking beta-blockers, compared with those not Taking beta-blockers (HR, ;95% CI, ; P=.02), whereas that in non- Diabetic participants with CHD was significantly lower inthose Taking beta-blockers (HR, ; 95% CI, ; P=.02). A propensity score matched Coxproportional hazards model yielded similar of -blockers may be associated with an increased risk of Mortality for Patients with diabetes and amongthe subset who have and Acronyms:BMI (body mass index), CHD (coronary heart disease), CHF (congestive heart failure), COPD (chronicobstructive pulmonary disease), HbA1c (hemoglobin A1c), HR (hazard ratio), MEC (mobile examinationcenter), NCHS (National Center for Health Statistics), NHANES (National Health and Nutrition ExaminationSurvey)For editorial comment, see page 401 Grant Support: This work was supported by grant 26860701 from the Japan Society for the Promotion of ScienceKAKENHI and a grant from the National Center for Global Health and Competing Interests.

4 The authors report no competing interests. 2017 mayo Foundation for Medical Education and ResearchView AllLog InLogin to existing accountForgot password?RegisterCreate a new accountPurchase access to this article$ USD|PDF Download and 24 HoursOnline AccessClaim AccessIf you are a current subscriber with SocietyMembership or an Account Number, claim youraccess to this titlePurchase a subscription to gain access to this andall other articles in this Access to see if you have access viayour access this article, please choose from the options below1 Visit ScienceDirectMayo Clinic Proceedings, Vol. 93, Issue 4 Effect of -Blockers and OtherAntihypertensive Drugs On the Risk ofMelanoma Recurrence and DeathMayo Clinic Proceedings, Vol. 88, Issue 11 Effect of -Adrenergic Blockers and OtherAntihypertensive Drugs on the Risk ofMelanoma Recurrence and Death IMayo Clinic Proceedings, Vol.

5 89, Issue 8 Effect of -Adrenergic Blockers and OtherAntihypertensive Drugs on the Risk ofMelanoma Recurrence and Death IIMayo Clinic Proceedings, Vol. 89, Issue 8In reply Effect of -Adrenergic Blockersand Other Antihypertensive Drugs on theRisk of Melanoma Recurrence and DeathMayo Clinic Proceedings, Vol. 89, Issue 8 Risk of All-Cause Mortality in Diabetic Patients Taking -Blockers - mayo Clinic (17)30845-5/fulltext[2018/04/11 20:28:06]Copyright 2018 Elsevier Inc. All rights reserved. | Privacy Policy | Terms & Conditions | Use of Cookies | About Us | Help & Contact | AccessibilityThe content on this site is intended for health on this site do not constitute a guarantee or endorsement by the journal, Association, or publisher of the quality or value of such product or of the claims made for it by itsmanufacturer.

6 < Previous ArticleNext Article >April 2018 Volume 93, Issue 4, Pages 409 418